No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PFE240712C29500
- 0.03
- +0.02+200.00%
15min DelayClose Jul 11 16:00 ET
0.14High0.02Low
0.06Open0.01Pre Close4.72K Volume3.17K Open Interest29.50Strike Price28.55KTurnover48.85%IV3.04%PremiumJul 12, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type0.0894Delta0.2654Gamma1146.40Leverage Ratio-0.0699Theta0.0000Rho102.54Eff Leverage0.0020Vega
Intraday
- 5D
- Daily
News
Pfizer to Advance Development of Modified-Release Formulation of Danuglipron
Pfizer (PFE) said Thursday it will conduct dose optimization studies of danuglipron in the second half of the year after selecting a once-daily, modified-release formulation of the drug candidate
Morgan Stanley Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $29
Morgan Stanley analyst Terence Flynn maintains $Pfizer(PFE.US)$ with a hold rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 64.8% and a
Truist Financial Keeps Their Buy Rating on Pfizer (PFE)
Pfizer's Danuglipron Progress Met With Cautious Optimism Amidst Competitive Landscape
Hold Rating on Pfizer: Caution Advised Amid Uncertainties Surrounding Danuglipron
Analysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Pfizer (PFE)
Comments
Why do you think $Pfizer(PFE.US$ decided to progress with Danuglipron? (![]()
Can't give up this huge market?
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
+1
3
1
Big potiental for Russell 2000, REITs & Bond markets in second half year of 2024.
AI stocks may be struggling in short term but fundamentals are still very strong. A little pullback is normal.
AI stocks may be struggling in short term but fundamentals are still very strong. A little pullback is normal.
loading...
12
1
Morning Movers
Gapping up
$Costco(COST.US$ shares saw an increase of nearly 1.34% as the company announced its first membership fee increase since 2017, raising the cost of its annual membership in the U.S. and Canada by $5 and its higher-tier plan by $10.
$Pfizer(PFE.US$ 's stock went up nearly 2.8% following the company's announcement that it will proceed with the development of a once-daily version of its weight loss pill, ...
Gapping up
$Costco(COST.US$ shares saw an increase of nearly 1.34% as the company announced its first membership fee increase since 2017, raising the cost of its annual membership in the U.S. and Canada by $5 and its higher-tier plan by $10.
$Pfizer(PFE.US$ 's stock went up nearly 2.8% following the company's announcement that it will proceed with the development of a once-daily version of its weight loss pill, ...
35
5
Read more